Beneficial effects of quercetin on obesity and diabetes

Open Nutraceuticals Journal

Volumn 4, Issue , 2011, Pages 189-198

  Aguirre, Leixuri ^a,b   Arias, Noemi ^a,b   Macarulla, M Teresa ^a,b   Gracia, Ana ^a,b   Portillo, Maria P ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cell cultures and animal models; Diabetes; Insulin resistance; Obesity; Quercetin

Indexed keywords

CYTOCHROME P450 2C8; INSULIN; QUERCETIN; RESVERATROL;

ARTICLE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HYPERPLASIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; KIDNEY TUBULE DISORDER; LIPOGENESIS; MOLECULAR PATHOLOGY; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ANIMALIA; BRASSICA OLERACEA VAR. BOTRYTIS; BRASSICA OLERACEA VAR. CAPITATA;

EID: 80455149952     PISSN: None     EISSN: 18763960     Source Type: Journal    
DOI: 10.2174/1876396001104010189     Document Type: Article

References (68)

1. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000; 130: S2073-S2085.
2. Mangels AR, Holden JM, Beecher GR, et al. Caretenoide contents of fruits and vegetables: an evaluation of analytical data. Am Diet Assoc 1993; 93: 284-296.
3. Graefe EU, Wittig J, Mueller S, et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001; 41: 492-499.
4. Walle T, Otake Y, Walle UK, Wilson FA. Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr 2000; 130: 2658-2661.
5. World Health Organization, "Fact sheet: Obesity and overweight," http://www.who.int/hpr/gs.fs.obesity.shtml [accessed: 15 July 2011].
6. Ahn J, Lee H, Suna K, Park J, Ha T. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathaways. Biochem Biophy Res 2008; 373: 545-549.
7. Motoyashiki T, Morita T, Ueki H. Involvement of the rapid increase in cAMP content in the Vanadate-Stimulated Release of Lipoprotein Lipase activity from rat fat pad. Biol Pharm Bull 1996; 19: 1412-1416.
8. Kuppusamy UR, Das NP. Effects of flavonoids on cyclic AMP phosphodiesterase and lipid mobilezation in rat adipocytes. Biochem Pharma 1992; 44: 1307-1315.
9. Hsu CL, Yen GC. Induction of cell apoptosis in 3T3-L1 preadipocytes by flavonoids is associated with their antioxidant activity. Mol Nutr Food Res 2006; 50: 1072-1079.
10. Stewart LK, Soileau JL, Ribnicky D, et al. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism 2008; 57 (Suppl 1): S39-S46.
11. Rivera L, Morón R, Sánchez M, et al. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats. Obesity 2008; 16: 2081-2087.
12. Liang C, Oest ME, Prater ME. Intrauterine exposure to high saturated fat diet elevates risk of adult-onset chronic diseases in C57BL/6 Mice. Birth Defects Research (Part B) 2009; 86: 377-384.
13. Ohkoshi E, Miyazaki H, Shindo K, et al. Constituents from the leaves of Nelumbo nucifera stimulate lipolysis in the white adipose tissue of mice. Planta Med 2007; 73: 1255-1259.
14. Kobori M, Masumoto S, Akimoto Y, Oike H. Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice, Mol Nutr Food Res 2011; 55: 530-540.
15. Kim JH, Kang MJ, Choi HN, et al. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr Res Pract 2011; 5(2): 107-111.
16. Wein S, Behm N, Petersen RK, et al. Quercetin enhances adiponectin secretion by a PPARγ independent mechanism. Eur J Pharm Sci 2010; 41: 16-22.
17. Egert S, Boesch-Saadatmandi C, Wolffram S, et al. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 2010; 140(2): 278-284.
18. Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharmacol 2010; 635(1/3): 1-8.
19. Walle T, Hsieh F, DeLegge MH, et al. High absorption but very low availability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-1382.
20. Walle T. Biovailability of resveratrol. Ann N Y Acad Sci 2011; 1215: 9-15.
21. De Santi C, Pietrabissa A, Mosca F, et al. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 2000; 30: 857-866.
22. Yang JY, Della-Fera MA, Rayalam S, et al. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci 2008; 82: 1032-1039.
23. Lai CY, Yang JY, Rayalam S, et al. Preventing Bone Loss and Weight Gain with Combinations of Vitamin D and Phytochemicals. J Med Food 2011 Jun 11. [Epub ahead of print]
24. American Diabetes Association. Diagnosis and classification of diabetes melitus. Diabetes care 2011; 34: S62-S69.
25. Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome a comprehensive perspective based on interactions between obesity, diabetes and inflammation. Am Heart Assoc 2005; 111: 1448-1454.
26. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
27. Bingley PJ, Mahon JL, Gale EA. Insulin resistance and progression to type 1diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2007; 31: 146-150.
28. Gregory S. Kelly ND. Quercetin. AMR 2011; 16: 2: 172-194.
29. Kwon O, Eck P, Chen S, et al. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J 2007; 21: 366-377.
30. Manzano S, Williamson G. Polyphenols and phenolic acids from strawberry and apple decrease glucose uptake and transport by human intestinal Caco-2 cells. Mol Nutr Food Res 2010; 54: 1773-1780.
31. Rosen OM. After insulin binds. Science 1987; 237(4821): 1452-1458.
32. Elberg G, Jinping Li, Leibovitch A, Shechter Y. Non-receptor cytosolic protein tyrosine kinases from various rat tissues. Biochim Et Biophy Acta 1995; 1269: 299-306.
33. Strobel P, Allard C, Pérez-Acle T, et al. Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Biochem J 2005; 386: 471-478.
34. Youl E, Bardy G, Magous R, et al. Quercetin potentiates insulin secretion and protects INS-1 pancreatic b-cells against oxidative damage via the ERK1/2 pathway. BJP 2010; 161(4): 799-814.
35. Longuet C, Broca C, Costes S, et al. Extracellularly regulated kinases 1/2 (p44/42 mitogen-ctivated protein kinases) phosphorylate synapsin I and regulate insulin secretion in the MIN6 beta-cell line and islets of Langerhans. Endocrinology 2005; 146: 643-654.
36. Eid HM, Martineau LC, Saleem A, et al. Stimulation of AMPactivated protein kinase and enhancement of basal glucose uptake in muscle cells by quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant Vaccinium vitis-idaea. Mol Nutr Food Res 2010; 54: 991-1003.
37. Zazworsky D, Nelson Bolin J, Gaubeca VB. Handbook of Diabetes Management, Springer, New York, NY 2005.
38. Santos JM, Ribeiro SB, Gaya AR, et al. Skeletal muscle pathways of contraction-enhanced glucose uptake. Int J Sports Med 2008; 29(10): 785-794.
39. Torres-Piedra M, Ortiz-Andrade R, Villalobos-Molina R, et al. A comparative study of flavonoid analogues on streptozotocinenicotinamide induced diabetic rats: Quercetin as a potential antidiabetic agent acting via 11b-Hydroxysteroid dehydrogenase type 1 inhibition. Eur J Med Chem 2010; 45: 2606-2612.
40. Vessal M, Hemmati M, Vasei M. Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. Comp Biochem Physiol C: Comp Pharmacol Toxicol 2003; 135: 357-364.
41. Coskun O, Kanter M, Korkmaz A, Oter S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β-cell damage in rat páncreas. Pharmacol Res 2005; 51: 117-123.
42. Kobori M, Masumoto S, Akimoto Y, Takahashi Y. Dietary quercetin alleviates diabetic symptoms and reduces streptozotocininduced disturbance of hepatic gene expression in mice. Mol Nutr Food Res 2009; 53: 859-868.
43. Rivera L, Morón R, Sánchez M, et al. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats. Obesity 2008; 16; 2081-2087.
44. Steward LK, Wang Z, Ribnicky D, et al. Failure of dietary quercetin to alter the temporal progression of insulin resistance among tissues of C57BL/6J mice during the development of diet-induced obesity. Diabetologia 2009; 52: 514-523.
45. Jung JY, Lim Y, Moon MS, et al. Onion peel extracts ameliorate hyperglycemia and insulin resistance in high fat diet/ streptozotocin-induced diabetic rats. Nutr Metab 2011; 8: 18.
46. Romero M, Jiménez R, Hurtado B, et al. Lack of beneficial metabolic effects of quercetin in adult spontaneous hypertensive rats. Eur J Pharmacol 2010; 627: 242-250.
47. Bjeldanes LF, Chang GW. Mutagenic activity of quercetin and related compounds. Science 1997; 197: 577-578.
48. Hardigree AA, Epler JL. Comparative mutagenesis of plant flavonoids in microbial systems. Mutat Res 1978; 58: 231-239.
49. Yoshida MA, Sasaki M, Sugimura K, Kawachi T. Cytogenetic effects of quercetin on cultured mammalian cells. Proc Jpn Acad Ser B 1980; 56: 443-447.
50. MacGregor JT. Mutagenicity studies of flavonoids in vivo and in vitro. Toxicol Appl Pharmacol 1979; 48: A47 (Abstract).
51. Ngomuo AJ, Jones RS. Genotoxicity studies of quercetin and shikimate in vivo in the bone marrow of mice and gastric mucosal cells of rats. Vet Hum Toxicol 1996; 38: 176-180.
52. Cierniak A, Papiez M, Kapiszewska M. Modulatory effect of quercetin on DNA damage, induced by etoposide in bone marrow cells and on changes in the activity of antioxidant enzymes in rats. Rocz Akad Med Bialymst 2004; 49: 167-169.
53. Ambrose AM, Robbins DJ, DeEds F. Comparative toxicities of quercetin and quercitrin. J Am Pharm Assoc Sci Ed 1952; 41: 119-112
54. Saito D, Shirai A, Matsushima T, Sugimura T, Hirono I. Testof carcinogenicity of quercetin, a widely distributed mutagen in food. Teratog Carcinog Mutagen 1980; 1: 213-221.
55. Morino K, Matsukara N, Kawachi T, Ohgaki H, Sugimura T, Hirono I. Carcinogenicity test of quercetin and rutin in goldenhamsters by oral administration. Carcinogenesis 1982; 3: 93-97.
56. Ruiz MJ, Fernández M, Estela JM, Asensi M, Mañes J, Picó Y. Short-term oral toxicity of quercetin and pterostibene in Swiss mice. Toxicol Lett 2006; 164S: S1-324 (Abstract P22-15).
57. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007; 45: 2179-2205.
58. Dunnick JK, Hailey JR. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundam Appl Toxicol 1992; 19: 423-431.
59. NTP, 1992. Toxicology and Carcinogenesis Studies of Quercetin (CAS No., 117-39-5) in F344/N Rats (Feed Study). NTP Technical Report Series, No. 409. National Toxicology Program (NTP), Research Triangle Park, North Carolina. Available from: http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr409.pdf.
60. Buening MK, Chang RL, Huang MT, Fortner JG, Wood AW, Conney AH. Activation and inhibition of benzo(a) pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 1981; 41: 67-72.
61. Cermak R, Wolffram S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr Drug Metab 2006; 7: 729-744.
62. KH Liu, MJ Kim, BH Jeon, et al. Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbalmedicines, including Epimedii herbal. J Clin Pharm Ther 2006; 31: 83-91.
63. Toda T, Eliasson E, Ask B, Inotsume N, Rane A. Roles of Different CYP Enzymes in the Formation of Specific Fluvastatin Metabolites by Human Liver Microsomes. Basic Clin Pharmacol Toxicol 2009; 105(5): 327-332.
64. O'Donnell CJ, Grime K, Courtney P, Slee D, Riley RJ. The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting. Drug Metab Dispos 2007; 35: 381-385.
65. Si D, Wang Y, Zhou IH, et al. Mechanism of CYP2C9 Inhibition by Flavones and Flavonols. Drug Metab Dispos 2009; 37: 629-634.
66. Choi JS, Piao YJ, Kang KW. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 2011; 34(4): 607-613.
67. Izzo AA. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42(3): 139-148.
68. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54(4): 349-356.